stockrowLite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023.
- EPS
- +5.80%
- Free cash flow
- +179.3%
Quarter to June 2026, against a year earlier
Follow LITS
Alert me
Lite Strategy, Inc. (LITS) EV/Sales
As of 6 November 2026, Lite Strategy, Inc. (LITS) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −9.9× (March 2020) to 109× (October 2018); the current reading is higher than 52% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −0.2× | — |
| FY2023 | −1.2× | — |
| FY2022 | −1.9× | — |
| FY2021 | 4.8× | (31.05%) |
| FY2020 | 7.0× | (67.29%) |
| FY2019 | 21.3× | (45.46%) |
| FY2018 | 39.1× | 2,540.13% |
| FY2017 | 1.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | −0.3× | — |
| Jun 2023 | −1.2× | — |
| Mar 2023 | −1.4× | — |
| Dec 2022 | −1.4× | — |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EYPT EyePoint, Inc. compare | −41.1× |
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| LITS Lite Strategy, Inc. | 0.3× |
| ALGS Aligos Therapeutics, Inc. compare | 0.4× |
| EDSA Edesa Biotech, Inc. compare | 28.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)